Abstract:BACKGROUND:Ovarian cancer is a common malignancy in the female reproductive system with a high mortality rate. The most important reason is multidrug resistance (MDR) of cancer chemotherapy. To reduce side effects, reverse resistance and improve efficacy for the treatment of ovarian cancer, a "core-shell" polymeric nanoparticle-mediated curcumin and paclitaxel co-delivery platform was designed.METHODS:Nuclear magnetic resonance confirmed the successful grafting of polyethylenimine (PEI) and stearic acid (SA) (PEI-SA), which is designed as a mother core for transport carrier. Then, PEI-SA was modified with hyaluronic acid (HA) and physicochemical properties were examined. To understand the regulatory mechanism of resistance and measure the anti-tumor efficacy of the treatments, cytotoxicity assay, cellular uptake, P-glycoprotein (P-gp) expression and migration experiment of ovarian cancer cells were performed. In addition, adverse reactions of nanoformulation to the reproductive system were examined.RESULTS:HA-modified drug-loaded PEI-SA had a narrow size of about 189 nm in diameters, and the particle size was suitable for endocytosis. The nanocarrier could target specifically to CD44 receptor on the ovarian cancer cell membrane. Co-delivery of curcumin and paclitaxel by the nanocarriers exerts synergistic anti-ovarian cancer effects on chemosensitive human ovarian cancer cells (SKOV3) and multi-drug resistant variant (SKOV3-TR30) in vitro, and it also shows a good anti-tumor effect in ovarian tumor-bearing nude mice. The mechanism of reversing drug resistance may be that the nanoparticles inhibit the efflux of P-gp, inhibit the migration of tumor cells, and curcumin synergistically reverses the resistance of PTX to increase antitumor activity. It is worth noting that the treatment did not cause significant toxicity to the uterus and ovaries with the observation of macroscopic and microscopic.CONCLUSION:This special structure of targeting nanoparticles co-delivery with the curcumin and paclitaxel can increase the anti-tumor efficacy without increasing the adverse reactions as a promising strategy for therapy ovarian cancer.

Supplementary Table 3 from Follicle-Stimulating Hormone Peptide Can Facilitate Paclitaxel Nanoparticles to Target Ovarian Carcinoma in Vivo

Supplementary Table 2 from Follicle-Stimulating Hormone Peptide Can Facilitate Paclitaxel Nanoparticles to Target Ovarian Carcinoma <i>In vivo</i>

Supplementary Table 1 from Follicle-Stimulating Hormone Peptide Can Facilitate Paclitaxel Nanoparticles to Target Ovarian Carcinoma <i>in Vivo</i>

Data from Follicle-Stimulating Hormone Peptide Can Facilitate Paclitaxel Nanoparticles to Target Ovarian Carcinoma <i>in Vivo</i>

Co-Delivery of Curcumin and Paclitaxel by "Core-Shell" Targeting Amphiphilic Copolymer to Reverse Resistance in the Treatment of Ovarian Cancer.

Preparation of RGD Peptide/Folate Acid Double-Targeted Mesoporous Silica Nanoparticles and Its Application in Human Breast Cancer MCF-7 Cells

Establishment of a new paclitaxel resistant cell line of human ovarian carcinoma and preliminary observation of its biology.

Tumor-Targeting Polycaprolactone Nanoparticles with Codelivery of Paclitaxel and IR780 for Combinational Therapy of Drug-Resistant Ovarian Cancer

Development And Evaluation Of A Novel Tpgs-Mediated Paclitaxel-Loaded Plga-Mpeg Nanoparticle For The Treatment Of Ovarian Cancer

Targeted paclitaxel nanoparticles modified with follicle-stimulating hormone β 81-95 peptide show effective antitumor activity against ovarian carcinoma.

The Inhibitory Effect of Paclitaxel Nanoparticles on Ovarian Cancer Xenografts and Lymphatic Targeting

Paclitaxel Nanoparticle Inhibits Growth of Ovarian Cancer Xenografts and Enhances Lymphatic Targeting.

Primary study on the treatment of rat ovarian carcinoma via the intraperitoneal administration of paclitaxel nanoparticles

Follicle-stimulating Hormone Polypeptide Modified Nanoparticle Drug Delivery System in the Treatment of Lymphatic Metastasis During Ovarian Carcinoma Therapy.

Treatment of Xenografted Ovarian Carcinoma Using Paclitaxel-loaded Ultrasound Microbubbles

[Preparation and in Vitro Targeting of Follicle Stimulating Hormone Polypeptide Modified Nanoparticles].

Antitumor Efficiency of D-α-Tocopheryl Polyethylene Glycol 1000 Succinate-b-Poly(ε-caprolactone-<I>ran</I>-lactide) Nanoparticle-Based Delivery of Docetaxel in Mice Bearing Cervical Cancer

Antitumor efficiency of D-alpha-tocopheryl polyethylene glycol 1000 succinate-b-poly(epsilon-caprolactone-ran-lactide) nanoparticle-based delivery of docetaxel in mice bearing cervical cancer.

Co-Delivery of Docetaxel and Curcumin via Nanomicelles for Enhancing Anti-Ovarian Cancer Treatment

Octreotide modified liposomes that co-deliver paclitaxel and neferine effectively inhibit ovarian cancer metastasis by specifically binding to the SSTR2 receptors

Folate-mediated Targeted and Intracellular Delivery of Paclitaxel Using a Novel Deoxycholic Acid-O-carboxymethylated Chitosan&ndash;folic Acid Micelles